MUSTANG BIO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
MUSTANG BIO, INC. (MBIO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$2.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-05
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.01M, a 113.64% decline year-over-year.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $7.39M.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$5.27M.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$17.81M, a 241.36% decline year-over-year.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $10.43M.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$145.00K.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$69.67M.
- MUSTANG BIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$33.96M, a 387.47% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.12M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$1.01M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $10.43M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $12.14M 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $5.82M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $7.39M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$145.00K 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$3.08M 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | -$2.34M 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | -$5.27M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$69.67M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | -$66.34M 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | -$60.52M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$17.81M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$33.96M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | -$18.25M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$2.25M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $12.60M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $11.81M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $23.07M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $32.12M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $31.57M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $36.39M 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $13.84M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $23.95M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$5.60M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $45.44M 10-K · filed 2021-03-24 | |||
| 2019-09-30 | $56.33M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $66.17M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $19.13M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$18.51M 10-K · filed 2020-03-16 | |||
| 2018-09-30 | -$16.68M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |